| 1 |
MAPK14
| [3] VEGF signaling pathway VEGF signaling pathway, Yersinia infection, Tuberculosis | D09639
D09639
|
Losmapimod
| [2] 113 113, 222 |
| 2 |
MAPK14
| [3] VEGF signaling pathway VEGF signaling pathway, Yersinia infection, Tuberculosis | D10959
D10959
|
Neflamapimod
| [1] 8 8 |
| 3 |
HLA-DMA
| [3] Type I diabetes mellitus Type I diabetes mellitus, Tuberculosis, Viral myocarditis | D04318
D04318
|
Glatiramer
| [4] 2 2, 13, 96, 156 |
| 4 |
HLA-DMB
| [3] Type I diabetes mellitus Type I diabetes mellitus, Tuberculosis, Viral myocarditis | D04318
D04318
|
Glatiramer
| [4] 2 2, 13, 96, 156 |
| 5 |
HLA-DOA
| [3] Type I diabetes mellitus Type I diabetes mellitus, Tuberculosis, Viral myocarditis | D04318
D04318
|
Glatiramer
| [4] 2 2, 13, 96, 156 |
| 6 |
HLA-DOB
| [3] Type I diabetes mellitus Type I diabetes mellitus, Tuberculosis, Viral myocarditis | D04318
D04318
|
Glatiramer
| [4] 2 2, 13, 96, 156 |
| 7 |
HLA-DPA1
| [3] Type I diabetes mellitus Type I diabetes mellitus, Tuberculosis, Viral myocarditis | D04318
D04318
|
Glatiramer
| [4] 2 2, 13, 96, 156 |
| 8 |
HLA-DPB1
| [3] Type I diabetes mellitus Type I diabetes mellitus, Tuberculosis, Viral myocarditis | D04318
D04318
|
Glatiramer
| [4] 2 2, 13, 96, 156 |
| 9 |
HLA-DQA1
| [3] Type I diabetes mellitus Type I diabetes mellitus, Tuberculosis, Viral myocarditis | D04318
D04318
|
Glatiramer
| [4] 2 2, 13, 96, 156 |
| 10 |
HLA-DQA2
| [3] Type I diabetes mellitus Type I diabetes mellitus, Tuberculosis, Viral myocarditis | D04318
D04318
|
Glatiramer
| [4] 2 2, 13, 96, 156 |
| 11 |
HLA-DQB1
| [3] Type I diabetes mellitus Type I diabetes mellitus, Tuberculosis, Viral myocarditis | D04318
D04318
|
Glatiramer
| [4] 2 2, 13, 96, 156 |
| 12 |
HLA-DRA
| [3] Type I diabetes mellitus Type I diabetes mellitus, Tuberculosis, Viral myocarditis | D04318
D04318
|
Glatiramer
| [4] 2 2, 13, 96, 156 |
| 13 |
HLA-DRB1
| [3] Type I diabetes mellitus Type I diabetes mellitus, Tuberculosis, Viral myocarditis | D04318
D04318
|
Glatiramer
| [4] 2 2, 13, 96, 156 |
| 14 |
HLA-DRB3
| [3] Type I diabetes mellitus Type I diabetes mellitus, Tuberculosis, Viral myocarditis | D04318
D04318
|
Glatiramer
| [4] 2 2, 13, 96, 156 |
| 15 |
HLA-DRB4
| [3] Type I diabetes mellitus Type I diabetes mellitus, Tuberculosis, Viral myocarditis | D04318
D04318
|
Glatiramer
| [4] 2 2, 13, 96, 156 |
| 16 |
HLA-DRB5
| [3] Type I diabetes mellitus Type I diabetes mellitus, Tuberculosis, Viral myocarditis | D04318
D04318
|
Glatiramer
| [4] 2 2, 13, 96, 156 |
| 17 |
IFNA1
| [1] Tuberculosis Tuberculosis | D09662
D09662
|
Rontalizumab
| [1] 49 49 |
| 18 |
IFNA1
| [1] Tuberculosis Tuberculosis | D09668
D09668
|
Sifalimumab
| [1] 49 49 |
| 19 |
IFNA2
| [1] Tuberculosis Tuberculosis | D09662
D09662
|
Rontalizumab
| [1] 49 49 |
| 20 |
IFNA2
| [1] Tuberculosis Tuberculosis | D09668
D09668
|
Sifalimumab
| [1] 49 49 |
| 21 |
IFNA4
| [1] Tuberculosis Tuberculosis | D09662
D09662
|
Rontalizumab
| [1] 49 49 |
| 22 |
IFNA4
| [1] Tuberculosis Tuberculosis | D09668
D09668
|
Sifalimumab
| [1] 49 49 |
| 23 |
IFNA5
| [1] Tuberculosis Tuberculosis | D09662
D09662
|
Rontalizumab
| [1] 49 49 |
| 24 |
IFNA5
| [1] Tuberculosis Tuberculosis | D09668
D09668
|
Sifalimumab
| [1] 49 49 |
| 25 |
IFNA6
| [1] Tuberculosis Tuberculosis | D09662
D09662
|
Rontalizumab
| [1] 49 49 |
| 26 |
IFNA6
| [1] Tuberculosis Tuberculosis | D09668
D09668
|
Sifalimumab
| [1] 49 49 |
| 27 |
IFNA7
| [1] Tuberculosis Tuberculosis | D09662
D09662
|
Rontalizumab
| [1] 49 49 |
| 28 |
IFNA7
| [1] Tuberculosis Tuberculosis | D09668
D09668
|
Sifalimumab
| [1] 49 49 |
| 29 |
IFNA8
| [1] Tuberculosis Tuberculosis | D09662
D09662
|
Rontalizumab
| [1] 49 49 |
| 30 |
IFNA8
| [1] Tuberculosis Tuberculosis | D09668
D09668
|
Sifalimumab
| [1] 49 49 |
| 31 |
IFNA10
| [1] Tuberculosis Tuberculosis | D09662
D09662
|
Rontalizumab
| [1] 49 49 |
| 32 |
IFNA10
| [1] Tuberculosis Tuberculosis | D09668
D09668
|
Sifalimumab
| [1] 49 49 |
| 33 |
IFNA13
| [1] Tuberculosis Tuberculosis | D09662
D09662
|
Rontalizumab
| [1] 49 49 |
| 34 |
IFNA13
| [1] Tuberculosis Tuberculosis | D09668
D09668
|
Sifalimumab
| [1] 49 49 |
| 35 |
IFNA14
| [1] Tuberculosis Tuberculosis | D09662
D09662
|
Rontalizumab
| [1] 49 49 |
| 36 |
IFNA14
| [1] Tuberculosis Tuberculosis | D09668
D09668
|
Sifalimumab
| [1] 49 49 |
| 37 |
IFNA16
| [1] Tuberculosis Tuberculosis | D09662
D09662
|
Rontalizumab
| [1] 49 49 |
| 38 |
IFNA16
| [1] Tuberculosis Tuberculosis | D09668
D09668
|
Sifalimumab
| [1] 49 49 |
| 39 |
IFNA17
| [1] Tuberculosis Tuberculosis | D09662
D09662
|
Rontalizumab
| [1] 49 49 |
| 40 |
IFNA17
| [1] Tuberculosis Tuberculosis | D09668
D09668
|
Sifalimumab
| [1] 49 49 |
| 41 |
IFNA21
| [1] Tuberculosis Tuberculosis | D09662
D09662
|
Rontalizumab
| [1] 49 49 |
| 42 |
IFNA21
| [1] Tuberculosis Tuberculosis | D09668
D09668
|
Sifalimumab
| [1] 49 49 |
| 43 |
IFNG
| [2] Type I diabetes mellitus Type I diabetes mellitus, Tuberculosis | D04242
D04242
|
Fontolizumab
| [1] 46 46 |
| 44 |
IFNG
| [2] Type I diabetes mellitus Type I diabetes mellitus, Tuberculosis | D11120
D11120
|
Emapalumab
| [2] 49 49, 107 |
| 45 |
IFNGR1
| [1] Tuberculosis Tuberculosis | D00747
D00747
|
Interferon gamma-1b
| [7] 18 18, 65, 85, 228, 299, 301, 326 |
| 46 |
IFNGR2
| [1] Tuberculosis Tuberculosis | D00747
D00747
|
Interferon gamma-1b
| [7] 18 18, 65, 85, 228, 299, 301, 326 |
| 47 |
IL1A
| [2] Type I diabetes mellitus Type I diabetes mellitus, Tuberculosis | D01583
D01583
|
Pirfenidone
| [11] 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
| 48 |
IL1A
| [2] Type I diabetes mellitus Type I diabetes mellitus, Tuberculosis | D06635
D06635
|
Rilonacept
| [4] 51 51, 106, 107, 266 |
| 49 |
IL1A
| [2] Type I diabetes mellitus Type I diabetes mellitus, Tuberculosis | D11253
D11253
|
Bermekimab
| [1] 51 51 |
| 50 |
IL1B
| [3] Type I diabetes mellitus Type I diabetes mellitus, Yersinia infection, Tuberculosis | D01583
D01583
|
Pirfenidone
| [11] 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
| 51 |
IL1B
| [3] Type I diabetes mellitus Type I diabetes mellitus, Yersinia infection, Tuberculosis | D06635
D06635
|
Rilonacept
| [4] 51 51, 106, 107, 266 |
| 52 |
IL1B
| [3] Type I diabetes mellitus Type I diabetes mellitus, Yersinia infection, Tuberculosis | D09315
D09315
|
Canakinumab
| [10] 46 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 |
| 53 |
IL1B
| [3] Type I diabetes mellitus Type I diabetes mellitus, Yersinia infection, Tuberculosis | D09911
D09911
|
Gevokizumab
| [4] 41 41, 50, 56, 269 |
| 54 |
IL6
| [3] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, Tuberculosis | D01583
D01583
|
Pirfenidone
| [11] 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
| 55 |
IL6
| [3] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, Tuberculosis | D08976
D08976
|
Pomalidomide
| [6] 28 28, 34, 51, 85, 227, 331 |
| 56 |
IL6
| [3] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, Tuberculosis | D09669
D09669
|
Siltuximab
| [2] 28 28, 331 |
| 57 |
IL6
| [3] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, Tuberculosis | D10080
D10080
|
Sirukumab
| [2] 41 41, 46 |
| 58 |
IL10
| [3] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, Tuberculosis | D01583
D01583
|
Pirfenidone
| [11] 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
| 59 |
IL12A
| [2] Type I diabetes mellitus Type I diabetes mellitus, Tuberculosis | D09214
D09214
|
Ustekinumab
| [17] 37 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 |
| 60 |
IL12B
| [2] Type I diabetes mellitus Type I diabetes mellitus, Tuberculosis | D09214
D09214
|
Ustekinumab
| [17] 37 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 |
| 61 |
JAK1
| [2] Tuberculosis Tuberculosis, Viral carcinogenesis | D09959
D09959
|
Ruxolitinib
| [1] 228 228 |
| 62 |
JAK1
| [2] Tuberculosis Tuberculosis, Viral carcinogenesis | D09970
D09970
|
Tofacitinib
| [15] 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 |
| 63 |
JAK1
| [2] Tuberculosis Tuberculosis, Viral carcinogenesis | D10308
D10308
|
Baricitinib
| [13] 41 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 |
| 64 |
JAK1
| [2] Tuberculosis Tuberculosis, Viral carcinogenesis | D10653
D10653
|
Peficitinib
| [1] 46 46 |
| 65 |
JAK1
| [2] Tuberculosis Tuberculosis, Viral carcinogenesis | D10871
D10871
|
Filgotinib
| [6] 46 46, 53, 96, 97, 222, 271 |
| 66 |
JAK1
| [2] Tuberculosis Tuberculosis, Viral carcinogenesis | D10944
D10944
|
Itacitinib
| [5] 46 46, 51, 60, 97, 228 |
| 67 |
JAK1
| [2] Tuberculosis Tuberculosis, Viral carcinogenesis | D10994
D10994
|
Upadacitinib
| [8] 40 40, 41, 46, 49, 96, 97, 107, 271 |
| 68 |
JAK2
| [1] Tuberculosis Tuberculosis | D09959
D09959
|
Ruxolitinib
| [1] 228 228 |
| 69 |
JAK2
| [1] Tuberculosis Tuberculosis | D09970
D09970
|
Tofacitinib
| [15] 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 |
| 70 |
JAK2
| [1] Tuberculosis Tuberculosis | D10308
D10308
|
Baricitinib
| [13] 41 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 |
| 71 |
JAK2
| [1] Tuberculosis Tuberculosis | D10653
D10653
|
Peficitinib
| [1] 46 46 |
| 72 |
NFKB1
| [3] Yersinia infection Yersinia infection, Tuberculosis, Viral carcinogenesis | D01146
D01146
|
Iguratimod
| [4] 46 46, 51, 53, 271 |
| 73 |
IL23A
| [1] Tuberculosis Tuberculosis | D09214
D09214
|
Ustekinumab
| [17] 37 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 |
| 74 |
IL23A
| [1] Tuberculosis Tuberculosis | D10400
D10400
|
Tildrakizumab
| [2] 162 162, 271 |
| 75 |
IL23A
| [1] Tuberculosis Tuberculosis | D10438
D10438
|
Guselkumab
| [5] 37 37, 41, 51, 96, 97 |
| 76 |
IL23A
| [1] Tuberculosis Tuberculosis | D10912
D10912
|
Brazikumab
| [2] 96 96, 97 |
| 77 |
IL23A
| [1] Tuberculosis Tuberculosis | D11052
D11052
|
Risankizumab
| [4] 37 37, 96, 97, 271 |
| 78 |
IL23A
| [1] Tuberculosis Tuberculosis | D11123
D11123
|
Mirikizumab
| [3] 37 37, 96, 97 |
| 79 |
PPP3CA
| [3] Wnt signaling pathway Wnt signaling pathway, VEGF signaling pathway, Tuberculosis | D00107
D00107
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
| 80 |
PPP3CA
| [3] Wnt signaling pathway Wnt signaling pathway, VEGF signaling pathway, Tuberculosis | D00184
D00184
|
Cyclosporine
| [44] 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 81 |
PPP3CA
| [3] Wnt signaling pathway Wnt signaling pathway, VEGF signaling pathway, Tuberculosis | D05480
D05480
|
Pimecrolimus
| [1] 160 160 |
| 82 |
PPP3CA
| [3] Wnt signaling pathway Wnt signaling pathway, VEGF signaling pathway, Tuberculosis | D08556
D08556
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
| 83 |
PPP3CA
| [3] Wnt signaling pathway Wnt signaling pathway, VEGF signaling pathway, Tuberculosis | D09033
D09033
|
Voclosporin
| [1] 222 222 |
| 84 |
PPP3CB
| [3] Wnt signaling pathway Wnt signaling pathway, VEGF signaling pathway, Tuberculosis | D00107
D00107
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
| 85 |
PPP3CB
| [3] Wnt signaling pathway Wnt signaling pathway, VEGF signaling pathway, Tuberculosis | D00184
D00184
|
Cyclosporine
| [44] 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 86 |
PPP3CB
| [3] Wnt signaling pathway Wnt signaling pathway, VEGF signaling pathway, Tuberculosis | D05480
D05480
|
Pimecrolimus
| [1] 160 160 |
| 87 |
PPP3CB
| [3] Wnt signaling pathway Wnt signaling pathway, VEGF signaling pathway, Tuberculosis | D08556
D08556
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
| 88 |
PPP3CB
| [3] Wnt signaling pathway Wnt signaling pathway, VEGF signaling pathway, Tuberculosis | D09033
D09033
|
Voclosporin
| [1] 222 222 |
| 89 |
PPP3CC
| [3] Wnt signaling pathway Wnt signaling pathway, VEGF signaling pathway, Tuberculosis | D00107
D00107
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
| 90 |
PPP3CC
| [3] Wnt signaling pathway Wnt signaling pathway, VEGF signaling pathway, Tuberculosis | D00184
D00184
|
Cyclosporine
| [44] 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 91 |
PPP3CC
| [3] Wnt signaling pathway Wnt signaling pathway, VEGF signaling pathway, Tuberculosis | D05480
D05480
|
Pimecrolimus
| [1] 160 160 |
| 92 |
PPP3CC
| [3] Wnt signaling pathway Wnt signaling pathway, VEGF signaling pathway, Tuberculosis | D08556
D08556
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
| 93 |
PPP3CC
| [3] Wnt signaling pathway Wnt signaling pathway, VEGF signaling pathway, Tuberculosis | D09033
D09033
|
Voclosporin
| [1] 222 222 |
| 94 |
PPP3R1
| [3] Wnt signaling pathway Wnt signaling pathway, VEGF signaling pathway, Tuberculosis | D00107
D00107
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
| 95 |
PPP3R1
| [3] Wnt signaling pathway Wnt signaling pathway, VEGF signaling pathway, Tuberculosis | D00184
D00184
|
Cyclosporine
| [44] 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 96 |
PPP3R1
| [3] Wnt signaling pathway Wnt signaling pathway, VEGF signaling pathway, Tuberculosis | D05480
D05480
|
Pimecrolimus
| [1] 160 160 |
| 97 |
PPP3R1
| [3] Wnt signaling pathway Wnt signaling pathway, VEGF signaling pathway, Tuberculosis | D08556
D08556
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
| 98 |
PPP3R1
| [3] Wnt signaling pathway Wnt signaling pathway, VEGF signaling pathway, Tuberculosis | D09033
D09033
|
Voclosporin
| [1] 222 222 |
| 99 |
PPP3R2
| [3] Wnt signaling pathway Wnt signaling pathway, VEGF signaling pathway, Tuberculosis | D00107
D00107
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
| 100 |
PPP3R2
| [3] Wnt signaling pathway Wnt signaling pathway, VEGF signaling pathway, Tuberculosis | D00184
D00184
|
Cyclosporine
| [44] 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
| 101 |
PPP3R2
| [3] Wnt signaling pathway Wnt signaling pathway, VEGF signaling pathway, Tuberculosis | D05480
D05480
|
Pimecrolimus
| [1] 160 160 |
| 102 |
PPP3R2
| [3] Wnt signaling pathway Wnt signaling pathway, VEGF signaling pathway, Tuberculosis | D08556
D08556
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
| 103 |
PPP3R2
| [3] Wnt signaling pathway Wnt signaling pathway, VEGF signaling pathway, Tuberculosis | D09033
D09033
|
Voclosporin
| [1] 222 222 |
| 104 |
MAPK11
| [3] VEGF signaling pathway VEGF signaling pathway, Yersinia infection, Tuberculosis | D09639
D09639
|
Losmapimod
| [2] 113 113, 222 |
| 105 |
MAPK11
| [3] VEGF signaling pathway VEGF signaling pathway, Yersinia infection, Tuberculosis | D10959
D10959
|
Neflamapimod
| [1] 8 8 |
| 106 |
MAPK13
| [3] VEGF signaling pathway VEGF signaling pathway, Yersinia infection, Tuberculosis | D09639
D09639
|
Losmapimod
| [2] 113 113, 222 |
| 107 |
MAPK13
| [3] VEGF signaling pathway VEGF signaling pathway, Yersinia infection, Tuberculosis | D10959
D10959
|
Neflamapimod
| [1] 8 8 |
| 108 |
RAF1
| [3] Vascular smooth muscle contraction Vascular smooth muscle contraction, VEGF signaling pathway, Tuberculosis | D06272
D06272
|
Sorafenib
| [2] 34 34, 86 |
| 109 |
RAF1
| [3] Vascular smooth muscle contraction Vascular smooth muscle contraction, VEGF signaling pathway, Tuberculosis | D08524
D08524
|
Sorafenib
| [2] 34 34, 86 |
| 110 |
BCL2
| [1] Tuberculosis Tuberculosis | D10679
D10679
|
Venetoclax
| [1] 28 28 |
| 111 |
RELA
| [3] Yersinia infection Yersinia infection, Tuberculosis, Viral carcinogenesis | D12181
D12181
|
Edasalonexent
| [1] 113 113 |
| 112 |
MAPK12
| [3] VEGF signaling pathway VEGF signaling pathway, Yersinia infection, Tuberculosis | D09639
D09639
|
Losmapimod
| [2] 113 113, 222 |
| 113 |
MAPK12
| [3] VEGF signaling pathway VEGF signaling pathway, Yersinia infection, Tuberculosis | D10959
D10959
|
Neflamapimod
| [1] 8 8 |
| 114 |
SRC
| [4] VEGF signaling pathway VEGF signaling pathway, Yersinia infection, Tuberculosis, Viral carcinogenesis | D03252
D03252
|
Bosutinib
| [2] 2 2, 67 |
| 115 |
SRC
| [4] VEGF signaling pathway VEGF signaling pathway, Yersinia infection, Tuberculosis, Viral carcinogenesis | D03658
D03658
|
Dasatinib
| [2] 51 51, 85 |
| 116 |
SRC
| [4] VEGF signaling pathway VEGF signaling pathway, Yersinia infection, Tuberculosis, Viral carcinogenesis | D06414
D06414
|
Dasatinib
| [2] 51 51, 85 |
| 117 |
SRC
| [4] VEGF signaling pathway VEGF signaling pathway, Yersinia infection, Tuberculosis, Viral carcinogenesis | D09664
D09664
|
Saracatinib
| [3] 6 6, 89, 272 |
| 118 |
SYK
| [2] Tuberculosis Tuberculosis, Viral carcinogenesis | D09347
D09347
|
Fostamatinib
| [4] 46 46, 49, 61, 66 |
| 119 |
TGFB1
| [1] Tuberculosis Tuberculosis | D09620
D09620
|
Fresolimumab
| [4] 51 51, 85, 222, 274 |
| 120 |
TGFB2
| [1] Tuberculosis Tuberculosis | D09620
D09620
|
Fresolimumab
| [4] 51 51, 85, 222, 274 |
| 121 |
TGFB3
| [1] Tuberculosis Tuberculosis | D09620
D09620
|
Fresolimumab
| [4] 51 51, 85, 222, 274 |
| 122 |
TNF
| [5] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Tuberculosis | D00742
D00742
|
Etanercept
| [17] 15 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285, 298 |
| 123 |
TNF
| [5] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Tuberculosis | D00754
D00754
|
Thalidomide
| [20] 2 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 |
| 124 |
TNF
| [5] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Tuberculosis | D01583
D01583
|
Pirfenidone
| [11] 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
| 125 |
TNF
| [5] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Tuberculosis | D02597
D02597
|
Adalimumab
| [18] 19 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 |
| 126 |
TNF
| [5] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Tuberculosis | D02598
D02598
|
Infliximab
| [27] 35 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 |
| 127 |
TNF
| [5] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Tuberculosis | D03441
D03441
|
Certolizumab pegol
| [8] 37 37, 46, 49, 96, 97, 107, 226, 271 |
| 128 |
TNF
| [5] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Tuberculosis | D04358
D04358
|
Golimumab
| [8] 46 46, 56, 84, 96, 97, 107, 270, 271 |
| 129 |
TNF
| [5] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Tuberculosis | D04687
D04687
|
Lenalidomide
| [8] 16 16, 26, 28, 34, 49, 284, 300, 331 |
| 130 |
TNF
| [5] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Tuberculosis | D05393
D05393
|
Pegsunercept
| [1] 46 46 |
| 131 |
TNF
| [5] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Tuberculosis | D08976
D08976
|
Pomalidomide
| [6] 28 28, 34, 51, 85, 227, 331 |
| 132 |
TNF
| [5] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Type II diabetes mellitus, Type I diabetes mellitus, Yersinia infection, Tuberculosis | D09944
D09944
|
Ozoralizumab
| [1] 46 46 |
| 133 |
C3
| [2] Tuberculosis Tuberculosis, Viral carcinogenesis | D11613
D11613
|
Pegcetacoplan
| [3] 2 2, 62, 222 |
| 134 |
VDR
| [1] Tuberculosis Tuberculosis | D00122
D00122
|
Calcifediol
| [2] 113 113, 299 |
| 135 |
VDR
| [1] Tuberculosis Tuberculosis | D00129
D00129
|
Calcitriol
| [9] 18 18, 37, 46, 49, 66, 96, 158, 235, 326 |
| 136 |
VDR
| [1] Tuberculosis Tuberculosis | D00187
D00187
|
Ergocalciferol
| [6] 46 46, 49, 84, 96, 97, 299 |
| 137 |
VDR
| [1] Tuberculosis Tuberculosis | D00188
D00188
|
Cholecalciferol
| [25] 6 6, 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 60, 65, 75, 84, 85, 96, 97, 98, 162, 202, 228, 271, 298, 299 |
| 138 |
VDR
| [1] Tuberculosis Tuberculosis | D00299
D00299
|
Dihydrotachysterol
| [2] 6 6, 85 |
| 139 |
VDR
| [1] Tuberculosis Tuberculosis | D00930
D00930
|
Paricalcitol
| [4] 19 19, 66, 218, 238 |
| 140 |
VDR
| [1] Tuberculosis Tuberculosis | D01125
D01125
|
Calcipotriol
| [2] 36 36, 51 |
| 141 |
VDR
| [1] Tuberculosis Tuberculosis | D01518
D01518
|
Alfacalcidol
| [8] 41 41, 46, 49, 50, 96, 107, 235, 238 |
| 142 |
VDR
| [1] Tuberculosis Tuberculosis | D07578
D07578
|
Eldecalcitol
| [1] 46 46 |
| 143 |
CASP9
| [3] VEGF signaling pathway VEGF signaling pathway, Tuberculosis, Viral myocarditis | D11195
D11195
|
Rimiducid
| [6] 19 19, 60, 65, 284, 285, 326 |
| 144 |
CD74
| [1] Tuberculosis Tuberculosis | D08944
D08944
|
Milatuzumab
| [1] 49 49 |